, May 30 (IANS) The antibody cocktail therapy was administered to a 72-year-old Covid positive patient who is a diabetic with chronic kidney disease, at the Fortis Hospital here on Sunday.Administered one dose of the cocktail intravenously, .
Updated Apr 14, 2021 | 18:28 IST
Ministry of AYUSH said this growth is reflective of the fast-growing adoption of AYUSH products and services by the public in the wake of COVID-19 pandemic AYUSH Ministry’s manufacturing unit IMPCL achieves highest ever turnover | Photo Credit: Thinkstock
Indian Medicines Pharmaceutical Corporation Limited (IMPCL), the public sector manufacturing unit of the Ministry of AYUSH has recorded a turnover of Rs 164.33 crore for the financial year 2020-21.
This is the highest number achieved in the company’s history and an all-time high profit of approximately Rs 12 crore for the year. In the previous year 2019-20 revenue figures of the company was Rs 97 crore. This growth is reflective of the fast-growing adoption of AYUSH products and services by the public in the wake of COVID-19 pandemic, the ministry said in a statement.
Covid vaccine will be free for 3 crore healthcare, frontline workers: PM
The confirmation by the PM came on the day the Centre signed a deal SII, which is manufacturing Covid-19 vaccine in India, to supply it nearly 11 million doses, costing Rs 200 each, in the first go.
Share Via Email
| A+A A- By Express News Service
NEW DELHI: Prime Minister Narendra Modi on Monday assured Chief Ministers that the Centre will fully bear the expenses of vaccination against Covid-19 for nearly 3 crore healthcare and frontline workers in the first phase as the government inked the first purchase agreement with the Serum Institute of India.
Amid concerns over new UK COVID-19 strain, vaccine maker submits data for emergency use
Apart from SII and Bharat Biotech, Pfizer has applied for the EUA so far but the US based pharma major has sought more time to make a detailed presentation before the Covid subject expert committee.
Share Via Email
| A+A A- By Express News Service
NEW DELHI: One of the two Indian vaccine makers Serum Institute of India and Bharat Biotech has presented additional data demanded by the apex drug regulator in response to their application for emergency use authorization of Covid vaccine.
Apart from SII and Bharat Biotech, Pfizer has applied for the EUA so far but the US based pharma major has sought more time to make a detailed presentation before the Covid subject expert committee of the Central Drugs Standards Control Organisation.